KOZIAR VASAKOVA, Martina, Jakub GREGOR, Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA, Martina STERCLOVA, Veronika MUELLER, Robert SLIVKA, Michael STUDNICKA, Martina PLACKOVA, Monika ZURKOVA, Jasna TEKAVEC-TRKANJEC, Martina DOUBKOVÁ and Petra OVESNÁ. Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study. RESPIRATORY MEDICINE. LONDON: W B SAUNDERS CO LTD, 2024, vol. 234, November-December 2024, p. 1-8. ISSN 0954-6111. Available from: https://dx.doi.org/10.1016/j.rmed.2024.107791.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study
Authors KOZIAR VASAKOVA, Martina (203 Czech Republic), Jakub GREGOR (203 Czech Republic, belonging to the institution), Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA, Martina STERCLOVA (203 Czech Republic), Veronika MUELLER, Robert SLIVKA, Michael STUDNICKA (203 Czech Republic), Martina PLACKOVA (203 Czech Republic), Monika ZURKOVA (203 Czech Republic), Jasna TEKAVEC-TRKANJEC, Martina DOUBKOVÁ (203 Czech Republic, belonging to the institution) and Petra OVESNÁ (203 Czech Republic, belonging to the institution).
Edition RESPIRATORY MEDICINE, LONDON, W B SAUNDERS CO LTD, 2024, 0954-6111.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30203 Respiratory systems
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.300 in 2022
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.rmed.2024.107791
UT WoS 001318539800001
Keywords in English Idiopathic pulmonary fibrosis; Treatment; Survival; Lung
Tags 14110215, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 8/10/2024 14:22.
Abstract
Background: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. Methods: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving anti- fibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. Results: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values-0.053 l/yr vs-0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. Conclusions: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. Trial registration: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.
PrintDisplayed: 10/10/2024 01:13